Pharsight

Linzess generic

Linzess is a drug owned by Allergan, which was first authorized for market use on August 30, 2012. It contains the active ingredient linaclotide and comes in a capsule; oral dosage form. The drug holds a total of 12 patents, all of which are currently active.

When will Linzess generic be available?

The availability of Linzess generic is determined by the expiration of its patents. The last patent to expire would be the one titled 'Treatments for gastrointestinal disorders' (US9708371), which is set to expire on August 16, 2033. Therefore, the earliest possible release of Linzess generic is projected to be after this date.

Linzess uses

Linzess, with its active ingredient linaclotide, is used for treating a range of gastroenterological disorders. This includes chronic idiopathic constipation and irritable bowel syndrome with constipation in adult patients. linaclotide's effectiveness in these conditions is due to its capability to improve bowel movements and relieve stomach pain.

Linzess patent expiration

Linzess holds a total of 12 patents. The patent with the significant impact on the release of Linzess generic is US9708371, titled 'Treatments for gastrointestinal disorders', which expires on August 16, 2033. Below are the details of the patent:

EPO Oppostions filed on Linzess

Linzess dosage

Want to ask something?